Medpace Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Medpace stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MEDP, but not buy additional shares or sell existing shares.
View analyst ratings for Medpace or view top-rated stocks.

Wall Street analysts have given Medpace a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Medpace wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Medpace saw a decline in short interest in the month of January. As of January 15th, there was short interest totaling 736,200 shares, a decline of 27.8% from the December 31st total of 1,020,000 shares. Based on an average daily trading volume, of 235,100 shares, the short-interest ratio is currently 3.1 days. Approximately 2.6% of the shares of the company are short sold.
View Medpace's Short Interest.

Medpace is scheduled to release its next quarterly earnings announcement on Tuesday, April 27th 2021.
View our earnings forecast for Medpace.

Medpace Holdings, Inc. (NASDAQ:MEDP) posted its earnings results on Sunday, February, 14th. The company reported $1.35 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.24 by $0.11. The firm had revenue of $259.68 million for the quarter, compared to analysts' expectations of $246.41 million. Medpace had a net margin of 13.87% and a trailing twelve-month return on equity of 17.67%.
View Medpace's earnings history.

Medpace's stock was trading at $83.64 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MEDP shares have increased by 94.2% and is now trading at $162.43.
View which stocks have been most impacted by COVID-19.

Medpace updated its FY 2021 After-Hours earnings guidance on Monday, February, 15th. The company provided earnings per share (EPS) guidance of 4.08-4.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.17. The company issued revenue guidance of $1.075-1.175 billion, compared to the consensus revenue estimate of $1.1 billion.

5 equities research analysts have issued 12 month price targets for Medpace's stock. Their forecasts range from $75.00 to $180.00. On average, they expect Medpace's share price to reach $121.83 in the next year. This suggests that the stock has a possible downside of 25.0%.
View analysts' price targets for Medpace or view top-rated stocks among Wall Street analysts.

268 employees have rated Medpace CEO August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among Medpace's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Medpace include Exact Sciences (EXAS), Incyte (INCY), Charles River Laboratories International (CRL), PPD (PPD), ICON Public (ICLR), PRA Health Sciences (PRAH), Syneos Health (SYNH), Exelixis (EXEL), Precigen (PGEN), National Research (NRC), Anavex Life Sciences (AVXL), Starpharma (SPHRY), Luna Innovations (LUNA), Auxly Cannabis Group (CBWTF) and Bioanalytical Systems (BASI).
View all of MEDP's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Square (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG).

(MEDP) raised $150 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Medpace's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.60%), Pendal Group Limited (2.30%), Price T Rowe Associates Inc. MD (2.18%), Renaissance Technologies LLC (1.69%), Dimensional Fund Advisors LP (1.68%) and Fuller & Thaler Asset Management Inc. (1.58%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Stephen P Ewald and Susan E Burwig.
View institutional ownership trends for Medpace.

MEDP stock was sold by a variety of institutional investors in the last quarter, including Fuller & Thaler Asset Management Inc., Renaissance Technologies LLC, Assenagon Asset Management S.A., Federated Hermes Inc., Charles Schwab Investment Management Inc., Schroder Investment Management Group, JPMorgan Chase & Co., and Barclays PLC. Company insiders that have sold Medpace company stock in the last year include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Stephen P Ewald, and Susan E Burwig.
View insider buying and selling activity for Medpace or view top insider-selling stocks.

MEDP stock was bought by a variety of institutional investors in the last quarter, including GW&K Investment Management LLC, Rice Hall James & Associates LLC, BlackRock Inc., Canada Pension Plan Investment Board, Boston Trust Walden Corp, Morgan Stanley, Rothschild & Co. Asset Management US Inc., and Wells Fargo & Company MN.
View insider buying and selling activity for Medpace or or view top insider-buying stocks.

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MEDP stock can currently be purchased for approximately $162.43.

Medpace has a market capitalization of $5.80 billion and generates $860.97 million in revenue each year. The company earns $100.44 million in net income (profit) each year or $3.02 on an earnings per share basis.

Medpace employs 3,400 workers across the globe.

The official website for Medpace is www.medpace.com.

Medpace is headquartered at 5375 MEDPACE WAY, CINCINNATI OH, 45227.

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]